A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions Results From the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seung-Whan | - |
dc.contributor.author | Park, Seong-Wook | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Yun, Sung-Cheol | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Lee, Cheol Whan | - |
dc.contributor.author | Kang, Soo-Jin | - |
dc.contributor.author | Park, Seung-Jung | - |
dc.contributor.author | Lee, Jae-Hwan | - |
dc.contributor.author | Choi, Si Wan | - |
dc.contributor.author | Seong, In-Whan | - |
dc.contributor.author | Lee, Nae-Hee | - |
dc.contributor.author | Cho, Yoon Haeng | - |
dc.contributor.author | Shin, Won-Yong | - |
dc.contributor.author | Lee, Seung-Jin | - |
dc.contributor.author | Lee, Se-Whan | - |
dc.contributor.author | Hyon, Min-Su | - |
dc.contributor.author | Bang, Duk-Won | - |
dc.contributor.author | Choi, Young-Jin | - |
dc.contributor.author | Kim, Hyun-Sook | - |
dc.contributor.author | Lee, Bong-Ki | - |
dc.contributor.author | Lee, Keun | - |
dc.contributor.author | Park, Hoon-Ki | - |
dc.contributor.author | Park, Chang-Bum | - |
dc.contributor.author | Lee, Sang-Gon | - |
dc.contributor.author | Kim, Min-Kyu | - |
dc.contributor.author | Park, Kyoung-Ha | - |
dc.contributor.author | Park, Woo-Jung | - |
dc.date.accessioned | 2021-08-12T05:46:02Z | - |
dc.date.available | 2021-08-12T05:46:02Z | - |
dc.date.issued | 2011-03-15 | - |
dc.identifier.issn | 0735-1097 | - |
dc.identifier.issn | 1558-3597 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/16641 | - |
dc.description.abstract | Objectives The purpose of this study was to determine whether cilostazol reduces intimal hyperplasia in patients undergoing long zotarolimus-eluting stent implantation (stent length: >= 30 mm) for native long coronary lesions (length: >= 25 mm). Background Restenosis after drug-eluting stent implantation remains a significant clinical problem in long coronary lesions. Methods Patients (n = 499) were assigned randomly to triple (aspirin, clopidogrel, and cilostazol, triple group: n = 250) or dual antiplatelet therapy (aspirin and clopidogrel and placebo, dual group: n = 249) for 8 months after long zotarolimus-eluting stent implantation. The primary end point was in-stent late loss at the 8-month angiography according to the intention-to-treat principle. Results The 2 groups had similar baseline characteristics. The in-stent (0.56 +/- 0.55 mm vs. 0.68 +/- 0.59 mm, p = 0.045) and in-segment (0.32 +/- 0.54 mm vs. 0.47 +/- 0.54 mm, p = 0.006) late loss were significantly lower in the triple versus dual group, as were 8-month in-stent restenosis (10.8% vs. 19.1%, p = 0.016), in-segment restenosis (12.2% vs. 20.0%, p = 0.028), and 12-month ischemic-driven target lesion revascularization (5.2% vs. 10.0%, p = 0.042) rates. At 12 months, major adverse cardiac events including death, myocardial infarction, and ischemic-driven target lesion revascularization tended to be lower in the triple group than the dual group (7.2% vs. 12.0%, p = 0.07). Percent intimal hyperplasia volume by volumetric intravascular ultrasound analysis was reduced from 27.1 +/- 13.2% for the dual group to 22.1 +/- 9.9% for the triple group (p = 0.017). Conclusions Patients receiving triple antiplatelet therapy after long zotarolimus-eluting stent implantation had decreased extent of late luminal loss, percent intimal hyperplasia volume, and angiographic restenosis, resulting in a reduced risk of 12-month target lesion revascularization compared with patients receiving dual antiplatelet therapy. (Triple Versus Dual Antiplatelet Therapy after ABT578-Eluting Stent; NCT00589927) (J Am Coll Cardiol 2011; 57: 1264-70) (C) 2011 by the American College of Cardiology Foundation | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions Results From the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.jacc.2010.10.035 | - |
dc.identifier.wosid | 000288160000004 | - |
dc.identifier.bibliographicCitation | Journal of the American College of Cardiology, v.57, no.11, pp 1264 - 1270 | - |
dc.citation.title | Journal of the American College of Cardiology | - |
dc.citation.volume | 57 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1264 | - |
dc.citation.endPage | 1270 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | cilostazol | - |
dc.subject.keywordAuthor | coronary artery disease | - |
dc.subject.keywordAuthor | triple antiplatelet therapy | - |
dc.subject.keywordAuthor | zotarolimus-eluting stent | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.